536 SHORT-TERM SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH PENTOXIFYLLINE vs. CORTICOSTEROID: A NON-INFERIORITY TRIAL – A PRELIMINARY REPORT

Kim, D.J.; Suk, Ki Tae; Park, S.H.; Tak, Won Young; Yim, Hyung Joon; Um, Soon-Ho; Yoon, Kevin; Kim, Y.S.; Lee, H.J.; Baik, S.K.; Lee, J.S.; Kim, I.H.; Kim, H.S.; Sohn, Jung Ho

doi:10.1016/s0168-8278(13)60538-3

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kim et al . 's study is ongoing; an interim analysis was published in 2011. A total of 78 patients with clinically diagnosed AH (alcohol history of >40 g/day and clinical and biochemical features of AH) were included without biopsy.…”

Section: Resultsmentioning

confidence: 99%

“…Three trials have compared pentoxifylline with prednisolone; two as papers and one in an interim report . One trial reported 28‐day outcomes, two reported both 28‐day and 6‐month outcomes.…”

Section: Resultsmentioning

confidence: 99%

“…There was significant heterogeneity between trials with regard to methodology. AH was defined by clinical Akriviadis et al 28 Peladagu et al 31 Sidhu et al 32 De et al 25 Kim et al 27 Lebrec et al 29 Mathurin et al 33 Garcia et al 26 Year Type of publication…”

Section: Methodological Differences Between Trialsmentioning

confidence: 99%

“…Risk of bias was assessed using criteria specified by the Cochrane group. Risk of bias was high in some papers [25][26][27] and low in others [28][29][30] (Table 2). CONSORT guidelines were used to assess the quality of trials (Tables S1 and S2).…”

Section: Quality Of Trials and Risk Of Biasmentioning

confidence: 99%

See 3 more Smart Citations

Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis

Parker

Armstrong

Corbett

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodological Differences Between Trialsmentioning

confidence: 99%

Section: Quality Of Trials and Risk Of Biasmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis

Parker

Armstrong

Corbett

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In the meta-analysis of three trials that compared the efficacy of PTX vs. prednisolone in severe AH, two as papers and one as an interim report, there were no significant differences between treatment groups. 63 , 69 – 71 In a recent multicenter randomized noninferiority trial comparing PTX vs. prednisolone, the authors concluded that the efficacy of PTX is not statistically equivalent to the efficacy of prednisolone, supporting prednisolone as a preferred option. 72 …”

Section: Response To Steroidsmentioning

confidence: 99%

Current Management of Alcoholic Hepatitis and Future Therapies

Saberi

Dadabhai

Jang

et al. 2016

JCTH

View full text Add to dashboard Cite

Alcohol is one of the most common etiologies of liver disease, and alcoholic liver disease overall is the second most common indication for liver transplantation in the United States. It encompasses a spectrum of disease, including fatty liver disease, alcoholic hepatitis (AH), and alcoholic cirrhosis. AH can range from mild to severe disease, with severe disease being defined as: Discriminant Function (DF) ≥ 32, or Model for End-stage Liver Disease (MELD) ≥ 21, or presence of hepatic encephalopathy. Management of the mild disease consists mainly of abstinence and supportive care. Severe AH is associated with significant mortality. Currently, there is no ideal medical treatment for this condition. Besides alcohol cessation, corticosteroids have been used with conflicting results and are associated with an inherent risk of infection. Overall steroids have shown short term benefit when compared to placebo, but they have no obvious long term benefits. Pentoxifylline does not improve survival in patients with severe AH and is no longer recommended based on the results of the STOPAH (Steroid Or Pentoxifylline for Alcoholic Hepatitis) trial. Anti-tumor necrosis factor (TNF) agents are associated with increased risk of life threatening infections and death. Currently, early stage trials are underway, mainly targeting novel pathways based on disease pathogenesis, including modulation of innate immune system, inhibition of gut-liver axis and cell death pathways, and activation of transcription factor farnesyl X receptor (FXR). Future treatment may lie in human induced pluripotent stem cell (iPSC) technology, which is currently under investigation for the study of pathogenesis, drug discovery, and stem cell transplantation. Liver transplantation has been reported with good results in highly selected patients but is controversial due to limited organ supply.

show abstract

Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease)

Buzzetti

Kalafateli

Thorburn

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Because of very low-quality evidence, there is uncertainty in the effectiveness of any pharmacological intervention versus no intervention in people with alcoholic hepatitis or severe alcoholic hepatitis. Based on low-quality evidence, propylthiouracil may decrease mortality in people with other alcohol-related liver diseases. However, these results must be confirmed by adequately powered trials with low risk of bias before propylthiouracil can be considered effective.Future randomised clinical trials should be conducted with approximately 200 participants in each group and follow-up of one to two years in order to compare the benefits and harms of different treatments in people with alcoholic hepatitis. Randomised clinical trials should include health-related quality of life and report serious adverse events separately from adverse events. Future randomised clinical trials should have a low risk of bias and low risk of random errors.

show abstract

536 SHORT-TERM SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH PENTOXIFYLLINE vs. CORTICOSTEROID: A NON-INFERIORITY TRIAL – A PRELIMINARY REPORT

Cited by 6 publications

References 0 publications

Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis

Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis

Current Management of Alcoholic Hepatitis and Future Therapies

Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease)

Contact Info

Product

Resources

About